Behavioral pharmacological properties of a novel cannabinoid 1′,1′-dithiolane Δ8-THC analog, AMG-3

@article{Antoniou2005BehavioralPP,
  title={Behavioral pharmacological properties of a novel cannabinoid 1′,1′-dithiolane $\Delta$8-THC analog, AMG-3},
  author={Katerina Antoniou and Andreas Galanopoulos and Styliani Vlachou and Therapia Kourouli and Victoria R. Nahmias and Kyriaki Thermos and George E. Panagis and Z Daifoti and Marios Marselos and Demetris P. Papahatjis and Christina Spyraki},
  journal={Behavioural Pharmacology},
  year={2005},
  volume={16},
  pages={499-510}
}
Newly developed cannabinoids may hold the promise of the development of useful and safe drugs. This study aimed to investigate the behavioral effects of the novel 1′,1′-dithiolane Δ8-THC analogue AMG-3, a cannabinomimetic molecule with high affinity for CB1/CB2 receptors. This analog was chosen for its binding affinity to these receptors, which is higher than that reported for Δ8-tetrahydrocannabinol (Δ8-THC). Behavioral responses were assessed after the administration of AMG-3 (1, 2, 4, 8 mg… Expand
Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties.
TLDR
It is concluded that cannabinoids exhibit reinforcing/rewarding properties in experimental animals mostly under particular experimental conditions, which is not the case for other drugs of abuse, such as opiates, psychostimulants, alcohol and nicotine. Expand
Lack of evidence for appetitive effects of Δ9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents
TLDR
Findings indicate that Δ9-THC, in contrast to other drugs of abuse, does not facilitate ICSS or support CPP under the present experimental conditions, but rather has a dose-dependent inhibitory influence on ICSS. Expand
Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the Future
TLDR
A comprehensive picture of the current status of what is known about the endocannabinoid system mechanisms that underlie modification of brain-reward processes is provided to provide the development of potential pharmacotherapies designed to treat reward-dysfunction-related disorders. Expand
Effects of endocannabinoid neurotransmission modulators on brain stimulation reward
TLDR
These results indicate that under the present experimental conditions endocannabinoid modulators do not exhibit reinforcing properties, but rather have inhibitory influence on reward processes. Expand
Regulation of brain reward by the endocannabinoid system: a critical review of behavioral studies in animals.
TLDR
It is suggested that the endocannabinoid system plays a major role in modulating motivation and reward processes and, thus, could lead to the development of potential therapeutic compounds for the treatment of reward-related disorders. Expand
An effort to discover the preferred conformation of the potent AMG3 cannabinoid analog when reaching the active sites of the cannabinoid receptors.
TLDR
A new approach using MD calculations in a simulated biological environment, thus the CB receptors surrounded by a lipid bilayer environment has been used (third generation) for the generation of the novel AMG3 analogs for optimal and selective binding affinities at CB1 and CB2 receptors by the de novo drug design modeling. Expand
Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
TLDR
The results suggest that endogenous and synthetic cannabinoids protect retinal amacrine neurons from AMPA excitotoxicity in vivo via a mechanism involving the CB1 receptors, and the PI3K/Akt and/or MEK/ERK1/2 signaling pathways. Expand
Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants
TLDR
The neurochemical mechanisms that produce the rewarding properties of JWH-018, which most likely contributes to the greater incidence of dependence associated with “Spice” use, will be described and reliable data regarding the abuse potential of these compounds will be gathered. Expand
Chronic WIN55,212-2 elicits sustained and conditioned increases in intracranial self-stimulation thresholds in the rat
TLDR
It is indicated that repeated WIN55,212-2 administration elicited a sustained increase in ICSS, i.e., phenomena of tolerance or sensitization were not observed, and cannabinoid-predictive stimuli that may gain affective salience and play an important role in maintaining cannabinoid administration are demonstrated. Expand
Animal Models of Drug Addiction
TLDR
The ICSS procedure provides unique ways to investigate the anatomical basis of reward and motivation and is an important tool for the assessment of the reward-facilitating and anhedonic effects of various drugs of abuse with addictive properties. Expand
...
1
2
...

References

SHOWING 1-10 OF 57 REFERENCES
1',1'-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties.
TLDR
The evidence indicates that CT-3 exhibits a large dissociation between its anti- inflammatory/analgesic effects and its ulcerogenic actions, and warrants clinical development as a novel anti-inflammatory and analgesic drug. Expand
Molecular characterization of a peripheral receptor for cannabinoids
TLDR
The cloning of a receptor for cannabinoids is reported that is not expressed in the brain but rather in macrophages in the marginal zone of spleen, which helps clarify the non-psychoactive effects of cannabinoids. Expand
Behavioral effects of cannabinoid agents in animals.
TLDR
In animals, cannabinoid agonists such as delta9-THC, WIN 55,212-2, and CP 55,940 produce a characteristic combination of four symptoms, hypothermia, analgesia, hypoactivity, and catalepsy, providing good evidence for the involvement of CB1-related mechanisms. Expand
Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils
TLDR
The activation of cannabinoid systems is a required, permissive element in the ability of cocaine, d-amphetamine, morphine, and Win 55212-2 to reinstate behaviour, i.e., to override stimulus satiation. Expand
Self-administration of Δ9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys
TLDR
THC can act as an effective reinforcer of drug-taking behavior in monkeys with no history of exposure to other drugs, suggesting that self-administration of THC by monkeys provides a reliable animal model of human marijuana abuse. Expand
Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand.
TLDR
Examination of the motor effects of AM356(R-methanandamide), an analog of AEA that possesses higher metabolic stability to amidase hydrolysis, shows that its effects were of shorter duration, as compared to THC, likely due to its rapid breakdown by an amidase activity. Expand
WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation
TLDR
Findings suggest that cannabinoids may interfere with brain-reward systems responsible for the expression of acute reinforcing properties of drugs of abuse, such as cocaine, and provide evidence that the cannabinoid system could be an interesting drug discovery and development target for the treatment of drug addiction. Expand
Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols.
TLDR
The synthesis and affinities for the CB1 and CB2 receptors of a series of novel delta 8-THC analogues in which the side-chain pharmacophores are conformationally more defined than in the parent molecule are described. Expand
Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats.
TLDR
A relatively modest influence, if any at all, of exogenous or endogenous cannabinoids on reward-relevant neurotransmission is indicated. Expand
The molecular basis of cannabinoid activity.
TLDR
The newly increased interest in cannabinoid research opens the door for a better understanding and potential treatment in cases of abuse as well as novel therapeutic opportunities through the design and synthesis of pharmacologically more selective analogs. Expand
...
1
2
3
4
5
...